Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1994-04-08
1998-09-29
Martinell, James
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
536 231, A61K 3170
Patent
active
058146199
ABSTRACT:
Certain oligonucleotides capable of inhibiting the production of p120, a cell proliferation-associated nucleolar protein, are provided. Oligonucleotides designed to be hybridizable with nucleic acids encoding nucleolar proteins are believed to be therapeutically useful. Certain of such oligonucleotides, hybridizable to MRNA encoding p120, were made and found to inhibit the synthesis of p120. The oligonucleotides of the invention are useful for the treatment of diseases characterized by hyperproliferation of cells. Methods of treatment and diagnosis of such diseases using these oligonucleotides are also provided.
REFERENCES:
patent: 5087617 (1992-02-01), Smith
patent: 5098890 (1992-03-01), Gewirtz et al.
patent: 5166195 (1992-11-01), Ecker
RNA Structure from A To Z, Tinoco, Jr., et al.,Cold Spring Harbor Symposia on Quantitative Biology, vol. LII, pp. 135-146 (1987).
RNA Secondary Structure is an Integral Part of the in vitro Mechanism of Attenuation in Simian Virus 40, Resnekov, et al., The Journal of Biological Chemistry, 264:9953 (1989).
CUUCGG Hairpins: Extraordinarily Stable RNA Secondary Structures Associated with Various Biochemical Processes, Tuerk, et al, Proc. Natl. acad. Sci. USA, 85:1364 (1988).
Busch, "The Final Common Pathway of Cancer: Presidetnial Address", Cancer Res. 50: 4830-4838 (1990).
Davis et al., "Nucleolar Antigen Found in Several Human Tumors But Not in the Nontumor Tissues Studied", Proc. Natl. Acad. Sci. U. S. A. 76: 892-896 (1979).
Fonagy et al., "Antisense-Mediated Specific Inhibition of P120 Protein Expression Prevents G.sub.1 -to S-Phase Transition", Cancer Res. 52:5250 (1992).
Freeman et al., "Identification and Characterization of a Human Proliferation-associated Nucleolar Antigen with a Molecular Weight of 120,000 Expressed in Early G.sub.1 Phase", Cancer Research. 48: 1244-1251 (1988).
Freeman et al., "Prognostic Significance of Proliferation Associated Nucleolar Antigen P120 in Human Breast Carcinoma", Cancer Research 51: 1973-1978 (1991).
Freeman and Bondada, "Inhibiton of Cell Proliferation by Microinjection of Antibodies to Nucleolar Antigen P120", Am. Assoc. Cancer Res. 31:261 (1990).
Larson et al., "Genomic Structure of the Human Proliferating Cell Nucleolar Protein P120", Cancer Comm. 2: 63-71 (1990).
Ochs et al., "Intranucleolar Localization of Human Proliferating Cell Nucleolar Antigen p120", Cancer Res. 48: 6523-6529 (1988).
Saijo et al., "The Effect of Antisense p120 Construct on p120 Expression and Cell Proliferation in Human Breast Cancer MCF-7 Cells", Cancer Letters 68: 95-104 (1993).
Wahl et al, Methods Enzymol. 152:399 (1987).
Larson et al, Entrez, Release 3.0, Feb. 15, 1993.
Perlaky et al, Cancer Res. 52: 428 (1992).
Isis Pharmacuticals, Inc.
Martinell James
LandOfFree
Oligonucleotide inhibition of P120 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oligonucleotide inhibition of P120, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oligonucleotide inhibition of P120 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-686440